Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Inclusion Criteria:

* Aged ≥ 18 years, regardless of gender.
* Expected survival time ≥ 3 months.
* ECOG performance status score of 0-1.
* Confirmed diagnosis of relapsed/refractory CD7-positive hematolymphoid malignancies at screening.
* Coagulation function, liver and kidney function, and cardiopulmonary function meeting the requirements.
* Ability to understand the trial and signed informed consent form.

Exclusion Criteria:

* A history of malignant tumors other than hematolymphoid malignancies within 5 years prior to screening, excluding carcinoma in situ.
* Positive results for virological tests or syphilis.
* Severe cardiac diseases.
* Unstable systemic diseases as determined by the investigator.
* Active or uncontrolled infections requiring systemic treatment within 7 days prior to screening, excluding mild urinary and reproductive system infections and upper respiratory tract infections.
* Pregnant or lactating women; female subjects planning to become pregnant within 2 years after cell infusion; or male subjects whose partners plan to become pregnant within 2 years after the subject's cell infusion.
* Subjects receiving systemic corticosteroid therapy within 7 days prior to screening, or those judged by the investigator to require long-term systemic corticosteroid therapy during the trial period, excluding inhaled or topical administration.
* Participation in other clinical studies within 1 month prior to screening.
* Evidence of central nervous system (CNS) involvement at screening, such as detection of tumor cells in cerebrospinal fluid (CSF) or imaging findings suggestive of CNS infiltration.
* Patients requiring long-term use of immunosuppressants as determined by the investigator at screening.
* A history of epilepsy or other central nervous system diseases.
* Patients with primary immunodeficiency diseases.
* Other circumstances deemed inappropriate for enrollment by the investigator.